177 related articles for article (PubMed ID: 22370309)
21. Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis.
Chen LX; Zhou ZR; Li YL; Ning GZ; Zhang TS; Zhang D; Feng SQ
PLoS One; 2015; 10(5):e0128032. PubMed ID: 26010450
[TBL] [Abstract][Full Text] [Related]
22. Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status.
Mok J; Brown C; Moore AEB; Min SS; Hampson G
Endocr Res; 2018 Aug; 43(3):195-202. PubMed ID: 29652557
[TBL] [Abstract][Full Text] [Related]
23. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
Fitzpatrick LA; Dabrowski CE; Cicconetti G; Gordon DN; Papapoulos S; Bone HG; Bilezikian JP
J Clin Endocrinol Metab; 2011 Aug; 96(8):2441-9. PubMed ID: 21593114
[TBL] [Abstract][Full Text] [Related]
24. [Daily subcutaneous injection of teriparatide : the progress and current issues].
Yano S; Sugimoto T
Clin Calcium; 2014 Jan; 24(1):35-43. PubMed ID: 24369278
[TBL] [Abstract][Full Text] [Related]
25. Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density.
Bachmann G; Kriegman A; Gonçalves J; Kianifard F; Warren M; Simon JA
Menopause; 2011 Aug; 18(8):851-6. PubMed ID: 21796066
[TBL] [Abstract][Full Text] [Related]
26. Using Osteoporosis Therapies in Combination.
McClung MR
Curr Osteoporos Rep; 2017 Aug; 15(4):343-352. PubMed ID: 28667435
[TBL] [Abstract][Full Text] [Related]
27. [The Importance of teriparatide in the treatment of osteoporosis].
Yamauchi M
Clin Calcium; 2016 Jun; 26(6):905-13. PubMed ID: 27230847
[TBL] [Abstract][Full Text] [Related]
28. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene.
Cosman F; Keaveny TM; Kopperdahl D; Wermers RA; Wan X; Krohn KD; Krege JH
J Bone Miner Res; 2013 Jun; 28(6):1328-36. PubMed ID: 23281041
[TBL] [Abstract][Full Text] [Related]
29. The novel non-steroidal selective androgen receptor modulator S-101479 has additive effects with bisphosphonate, selective estrogen receptor modulator, and parathyroid hormone on the bones of osteoporotic female rats.
Furuya K; Yamamoto N; Ohyabu Y; Makino A; Morikyu T; Ishige H; Kuzutani K; Endo Y
Biol Pharm Bull; 2012; 35(7):1096-104. PubMed ID: 22791158
[TBL] [Abstract][Full Text] [Related]
30. Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate.
Cosman F; Nieves JW; Zion M; Garrett P; Neubort S; Dempster D; Lindsay R
J Clin Endocrinol Metab; 2015 Jul; 100(7):2769-76. PubMed ID: 25961136
[TBL] [Abstract][Full Text] [Related]
31. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
Cosman F; Wermers RA; Recknor C; Mauck KF; Xie L; Glass EV; Krege JH
J Clin Endocrinol Metab; 2009 Oct; 94(10):3772-80. PubMed ID: 19584192
[TBL] [Abstract][Full Text] [Related]
32. Anabolic therapies for osteoporosis.
Uihlein AV; Leder BZ
Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
[TBL] [Abstract][Full Text] [Related]
33. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
34. [Teriparatide: human recombinant parathyroid hormone (1-34) as a daily subcutaneous injection].
Sowa H; Hamaya E; Yamamoto T
Clin Calcium; 2011 Jan; 21(1):9-16. PubMed ID: 21187589
[TBL] [Abstract][Full Text] [Related]
35. The role of teriparatide in sequential and combination therapy of osteoporosis.
Meier C; Lamy O; Krieg MA; Mellinghoff HU; Felder M; Ferrari S; Rizzoli R
Swiss Med Wkly; 2014; 144():w13952. PubMed ID: 24896070
[TBL] [Abstract][Full Text] [Related]
36. [Once-weekly teriparatide treatment on osteoporosis].
Nakano T
Clin Calcium; 2014 Jan; 24(1):100-5. PubMed ID: 24369286
[TBL] [Abstract][Full Text] [Related]
37. Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis.
Bilezikian JP; Rubin MR
Curr Osteoporos Rep; 2006 Mar; 4(1):5-13. PubMed ID: 16527002
[TBL] [Abstract][Full Text] [Related]
38. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
Leder BZ; Tsai JN; Jiang LA; Lee H
Bone; 2017 May; 98():54-58. PubMed ID: 28286299
[TBL] [Abstract][Full Text] [Related]
39. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
Hashimoto Y; Wakayama N; Miyauchi A
Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
[TBL] [Abstract][Full Text] [Related]
40. [Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium].
Uebelhart D; Frey D; Frey-Rindova P; Goerres G; Michel BA
Z Rheumatol; 2003 Dec; 62(6):512-7. PubMed ID: 14685711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
